熱烈祝賀恩大細(xì)胞基因工程有限公司又榮獲一項發(fā)明專利證書——一種含有NK細(xì)胞的藥物組合物及其治療癌癥的用途。（Congratulations to Enda Cell Genetic Engineering Co., Ltd. for another invention patent certificate-a pharmaceutical composition containing NK cells and its use in treating cancer.）

本發(fā)明提供了一種含有NK細(xì)胞的藥物組合物及其治療癌癥的用途，其中組合物包含發(fā)明人優(yōu)化得到的NK細(xì)胞以及新制備的靶向CD38的抗體。所述NK細(xì)胞的制備方法通過磁珠篩選以及特異性的誘導(dǎo)優(yōu)化獲得了高活性、高純度的NK細(xì)胞，所述靶向CD38的單抗也具有較好的結(jié)合特性以及特異性。該組合物能夠有效的抑制多發(fā)性骨髓瘤移植瘤的生成，具有極佳的應(yīng)用價值。（The present invention provides a pharmaceutical composition containing NK cells and its use for treating cancer, wherein the composition comprises NK cells optimized by the inventor and a newly prepared antibody targeting CD38. The preparation method of the NK cells obtains NK cells with high activity and purity through magnetic bead screening and specific induction optimization. The CD38-targeted monoclonal antibody also has good binding characteristics and specificity. The composition can effectively inhibit the formation of multiple myeloma transplantation tumors, and has excellent application value.）

近年來，恩大細(xì)胞基因著重加大對科研的投入力度，積極開展技術(shù)創(chuàng)新工作，通過多年的努力，公司有了大量的專利儲存量，到目前恩大細(xì)胞基因先后獲得專利證書7項；相關(guān)著作權(quán)登記證書21項，這些專利成果為公司開拓市場，提高公司的核心競爭力，提供了強有力的科技支撐。在未來的發(fā)展中，恩大細(xì)胞基因?qū)⒏幼⒅刈灾鲃?chuàng)新能力的發(fā)展，把持續(xù)創(chuàng)新能力作為企業(yè)發(fā)展的固化機制，為企業(yè)持續(xù)、健康、快速發(fā)展提供強有力的支撐，力爭成為引領(lǐng)行業(yè)發(fā)展的新標(biāo)桿?。↖n recent years, NDA Cell Gene has focused on increasing its investment in scientific research and actively carried out technological innovation. Through years of hard work, the company has a certain amount of patent storage. Up to now, NDA Cell Gene has obtained 6 patent certificates; software; There are 21 copyright registration certificates. These patent achievements have provided strong scientific and technological support for the company to open up the market and improve the company's core competitiveness. In the future development, Enda Cell Genes will pay more attention to the development of independent innovation capabilities, and regard continuous innovation capabilities as a solidification mechanism for corporate development, providing strong support for the continuous, healthy and rapid development of the company, and strive to become a leader in the development of the industry. New benchmark!）